Baystreet Staff - Wednesday, May 11, 2016 Helix BioPharma Corp. 10:00 AM EST - Helix BioPharma Corp. : Announced that the first patient was dosed in the Phase II component of study LDOS002. Helix BioPharma Corp. shares T.HBP are trading unchanged at $2.00.